Virtual events on interventional oncology
Watch our latest virtual symposia and webinars on interventional oncology topics, including Y-90 therapy with TheraSphereTM glass microspheres, personalised dosimetry, cryoablation, peripheral embolisation and more.
Current UK Landscape of Bone & Soft Tissue Ablation | BSIR Webinar November 29th, 2023
Mar 12, 2024
In this webinar replay, you will learn more about various cryoablation topics: the role of ST&B ablation in cancer management, paediatric soft tissue tumours, Morton's Neuroma, Sarcoma, Malignant Bone, evaluation of BS&T ablation in the UK.
Moderators: Dr. Steve Bandula and Dr. Leonard King
Cryoablation of renal tumors: Treating more patients per day – Is conscious sedation the solution?
Sep 29, 2020
Prof. Ole Graumann provides tips and tricks for treating the right RCC patients with conscious sedation including needle placement and post treatment recovery.
Renal Cryoablation – Conscious sedation and optimization of patient workflow
Sep 12, 2020
Prof. Ole Graumann introduces different conscious sedation methods and explains how it can optimize patient workflow in a cost effective way.
Advancing the Science in Lung Cryoablation
Aug 25, 2020
Dr Matthew Callstrom speaks about the results from the SOLSTICE study which evaluate the safety and efficacy of cryoablation to treat pulmonary metastatic disease.
Ice to success. Renal Cryoablation from an Expert´s Perspective
Jul 09, 2020
Learn from two experts, coming from different perspectives: Interventional Radiology and Urology. Dr David Breen and Dr Brnolf Lagerveld discusses technique & optimization, patient selection and limitations, tips & tricks, RCC evidence and how to drive collaboration.
Discover your options and radial access horizons with TRUSELECT™
Feb 10, 2021
Prof. Mark W. Little describes the technical aspects of Transradial Access in peripheral interventions utilizing TRUSELECT 2.0F microcatheter and recommend a framework for transition to a radial strategy.
The power of visibility with DC Bead LUMI™ – Case based discussion
Dec 08, 2020
Through a case based discussion Dr. Tobias Jakobs explains when, why and how he uses DC Beads LUMI in HCC patients.
TRUSELECTivity in Small Vessel and Prostate Artery Embolisation. Why TRUSELECT™
Nov 25, 2020
Prof. Florian Wolf shares cases with the newly launched TRUSELECT 2F microcatheter and explains when and why to use it in small vessels, tortuous or distal anatomies.
Nov 10, 2020
Watch our DC Bead innovation team, Pedro Garcia and Venisha Patel, expertly guide you through DC Bead™ drug loading process and their experience in pharmacy. Understand the development and advancements of DC Bead™ and DC Bead LUMI™ and gain knowledge and understanding of IFU loading instructions and regulations.
DEB-TACE Management and TACE in Combination Therapy - Dr Roman Kloeckner
Oct 15, 2020
Third of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) cTACE vs DEB-TACE, at minute 00:37 2) When to switch to systemic therapy, at minute 01:36 3) Combination therapy, at minute 03:03 - TACE + Ablation - TACE + TKI - TACE + Immunotherapy
DEB-TACE with DC Bead - Clinical considerations - Dr Roman Kloeckner
Oct 15, 2020
Second of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) Indications for TACE - stage migration, at minute 0:27 2) Pre-, intra- and postinterventional imaging, at minute 1:42 3) Cases TACE vs SIRT, at minute 5:55
DEB-TACE with DC Bead - Technical considerations - Dr Roman Kloeckner
Oct 15, 2020
First of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) Catheters and Access Approaches, at minute 0:30 2) Bead Sizes, at minute 5:29 3) Application Technique and Mixing, at minute 07:55 4) Selectivity and Endpoint, at minute 09:35
Beads innovations in clinical usage: DC Bead™ to DC Bead LUMI™
Oct 13, 2020
Pedro Garcia provides insight on the innovation and development to create DC Bead LUMI. Dr Pete Littler shares his clinical experience where using DC Bead LUMI makes a difference.
DEB-TACE with DC Bead™ vs cTACE from a clinical and health economic perspective
Sep 14, 2020
Prof. Irene Bargellini shares why DC Beads™ is a cost-effective intervention vs cTACE in HCC and the patient benefits and QALY when treated with DEB-TACE.
New Approach in Endoleak Type II Management
Jul 03, 2020
Prof. Gargiulo, Prof. Froio and Dr Mascoli discuss the predictive factors in indentifying high-risk patients as well as outcomes of routine sac embolisation in the patient population.
The power of visibility with DC Bead LUMI™ – Case based discussion
Dec 08, 2020
Through a case based discussion Dr. Tobias Jakobs explains when, why and how he uses DC Beads LUMI in HCC patients.
Nov 10, 2020
Watch our DC Bead innovation team, Pedro Garcia and Venisha Patel, expertly guide you through DC Bead™ drug loading process and their experience in pharmacy. Understand the development and advancements of DC Bead™ and DC Bead LUMI™ and gain knowledge and understanding of IFU loading instructions and regulations.
DEB-TACE Management and TACE in Combination Therapy - Dr Roman Kloeckner
Oct 15, 2020
Third of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) cTACE vs DEB-TACE, at minute 00:37 2) When to switch to systemic therapy, at minute 01:36 3) Combination therapy, at minute 03:03 - TACE + Ablation - TACE + TKI - TACE + Immunotherapy
DEB-TACE with DC Bead - Clinical considerations - Dr Roman Kloeckner
Oct 15, 2020
Second of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) Indications for TACE - stage migration, at minute 0:27 2) Pre-, intra- and postinterventional imaging, at minute 1:42 3) Cases TACE vs SIRT, at minute 5:55
DEB-TACE with DC Bead - Technical considerations - Dr Roman Kloeckner
Oct 15, 2020
First of three podcasts on DEB-TACE with DC Bead Dr Roman Kloeckner will discuss 1) Catheters and Access Approaches, at minute 0:30 2) Bead Sizes, at minute 5:29 3) Application Technique and Mixing, at minute 07:55 4) Selectivity and Endpoint, at minute 09:35
Beads innovations in clinical usage: DC Bead™ to DC Bead LUMI™
Oct 13, 2020
Pedro Garcia provides insight on the innovation and development to create DC Bead LUMI. Dr Pete Littler shares his clinical experience where using DC Bead LUMI makes a difference.
DEB-TACE with DC Bead™ vs cTACE from a clinical and health economic perspective
Sep 14, 2020
Prof. Irene Bargellini shares why DC Beads™ is a cost-effective intervention vs cTACE in HCC and the patient benefits and QALY when treated with DEB-TACE.
ECIO 2023 - Present and future of cryoablation: where are we heading?
Apr 18, 2023
A leading panel of experts at #ECIO2023 assisted us in deep diving into cryoablation therapy to discover more about its latest evidence and application and application in MSK, RCC and Breast tumors through our sessions.
Moderator: Prof. Laura Crocetti
EANM 2022 - Y-90 Glass Microspheres, Personalised Dosimetry, Gudelines and Clinical Data
Oct 16, 2022
A panel of international experts share the latest TARE clinical evidence through cases and discussions and review how this translate into the guidelines for both primary and secondary liver cancer.
Moderator: Prof. Ken Herrmann
EASL Liver Cancer Summit 2022 - Radioembolisation in the BCLC and beyond: An MDT approach
Feb 18, 2022
EASL Digital Liver Cancer Summit 2022 - an international congress dedicated to the latest data and findings in the fight against primary liver cancer. Watch our virtual symposium on Radioembolisation and the latest data from the official update of the Barcelona Clinic Liver Cancer (BCLC).
The results of the Target Study with Prof. Riad Salem and Prof. Marnix Lam
Feb 17, 2022
Target Study confirms the significance of tumour absorbed dose to tumour response and overall survival
The Cost-Effectiveness of TheraSphere in Patients with Hepatocellular Carcinoma
Feb 16, 2022
Stuart Mealing at ECIO 2021 shows the Cost-Effectiveness of SIRT in early and intermediate staged HCC patients
EPOCH: The phase III RCT with Y-90 TheraSphere™
Feb 15, 2022
Evaluating 2nd line treatment with Y-90 TheraSphere in patients with colorectal liver metastases. CIRSE 2021 Congress, Boston Scientific symposium, September 26th 2021
Therasphere Summit 2021 Best practices in MDT: Patient cases to improve decision making in CLM
Nov 17, 2021
Our expert panel discuss the role of SIRT in CLM patients with 4 case examples
Therasphere Summit 2021 Next level: Personalised dosimetry improve the outcomes of patients with CLM
Nov 17, 2021
Prof. Marnix Lam explains how to integrate personalized dosimetry with Simplicity to the treatment of CLM patients.
Therasphere Summit 2021 Round table: What does EPOCH data mean & How should IRs approach Med. Oncs.
Nov 17, 2021
Results of EPOCH study and how IRs should approach Medical Oncologists with this new data.
Therasphere Summit 2021: EPOCH Take Home messages from the perspective of a Medical Oncologist
Nov 17, 2021
Key take home messages from EPOCH. Why EPOCH is different from other Phase 3 clinical trials in CLM?
Therasphere Summit 2021: Expanding the options for the treatment of CLM
Nov 17, 2021
Dr. Irene Bargellini introduces the TheraSphere Summit 2021: expanding the options for the treatment of colorectal liver metastases.
Therasphere Summit 2021: key clinical elements from combined SIRT/Systemic Therapies phase 3
Nov 17, 2021
Are there key clinical elements explaining the differences in outcomes from combined SIRT/Systemic Therapies phase 3 clinical trials? Prof. Jens Ricke walked us through it.
Therasphere Summit 2021: Level 1 evidence from Phase III Epoch Trial
Nov 17, 2021
Prof. Theysohn shares level 1 evidence results from Phase III Epoch Trial
Therasphere Summit 2021: mCRC Treatments over the past 10 years, Advances & Unmet Need with Q & A
Nov 17, 2021
Prof. Dirk Arnold gives an overview of the CLM treatment – what has been changed over last few years and what are the unmet needs
Optimizing SIRT Planning for Superior Patient Outcomes
Oct 30, 2020
EANM congress, Boston Scientific symposium October 30th 2020
Combination of SIRT with Systemic Therapy in HCC
Oct 09, 2020
Prof. Jens Ricke shares the existing data about combination of SIRT with Systemic Therapy in HCC
Immunotherapy – What we see until now? What do we expect in future?
Oct 09, 2020
Prof. Heiner Wedemeyer presents existing data on immunotherapy for the treatment of HCC and future expectations
Oct 09, 2020
Dr Julien Edeline speaks about what can SIRT offer for intrahepatic cholangiocarcinoma patients.
Where we are with SIRT in mCRC? What do we expect in future?
Oct 09, 2020
Dr Pilar Garcia Alfonso reviews the current clinical evidence for SIRT in mCRC and describes the EPOCH trial
Dosimetry guidelines for TheraSphere in HCC
Oct 08, 2020
Prof. Marnix Lam shares the recommendations of an international multidisciplinary working group about the clinical and dosimetric considerations for TheraSphere in HCC treatment
Dosimetry-guided treatment planning in Nuclear Medicine
Oct 08, 2020
Prof. Mark Konijnenberg shares how dosimetry-guided treatment should provide the right balance between harm and benefit; eg low toxicity and increased survival.
Personalised dosimetry in real life: the PROACTIF experience
Oct 08, 2020
Prof. Thierry de Baere introduces the PROACTIF experience and focuses on personalised dosimetry
Personalised dosimetry: from concept to reality with DOSISPHERE-01 trial
Oct 08, 2020
Prof. Etienne Garin discusses personalised dosimetry from concept to reality with DOSISPHERE-01 trial
How SIRT can fill the gaps? Can SIRT lead to curative treatment in HCC?
Oct 07, 2020
Dr Droz Dit Busset discussed the place of SIRT in the current HCC treatment algorithm and whether it can lead to cure.
Personalized Dosimetry – an option or a must?
Oct 07, 2020
Dr Lambros Tselikas speaks about personalized dosimetry in SIRT and explains why it is a must.
Oct 07, 2020
Prof. Irene Bargellini discusses what SIRT could offer during the Covid-19 pandemic
Where we are with the existing guidelines for the treatment of HCC
Oct 07, 2020
Dr Maria Varela reviews the existing guidelines, identifies the gaps and the possible role of SIRT in the HCC treatment
Optimizing SIRT planning for superior patient outcomes
Sep 13, 2020
Personalised dosimetry: unique to glass microspheres. Dr Yan Rolland
Optimizing SIRT planning for superior patient outcomes
Sep 13, 2020
Case examples of personalised dosimetry in curative and palliative scenarios. Dr Rafael Duran.
Optimizing SIRT planning for superior patient outcomes
Sep 13, 2020
Prof. Eric Vibert introduces the symposium
Optimizing SIRT planning for superior patient outcomes. Discussion and Q&A
Sep 13, 2020
Panelists discussion
Optimizing SIRT planning for superior patient outcomes. Refine your SIRT Planning
Sep 13, 2020
Prof. Marnix Lam
Y90 A Step Towards Curative Therapies for HCC (ILCA symposium)
Sep 13, 2020
00:00 Talia Baker shares long term outcomes of liver transplant 11:16 Pete Littler shares cases with SIRT for downstaging 22:03 Julien Edeline provides his view on positioning SIRT in the treatment algorithm
Lead the way: Personalise your SIRT dosimetry with TheraSphere™ and Simplicit90Y™
Jul 30, 2020
Prof. Boris Guiu and Prof. Etienne Garin speak on the unique clinical evidence demonstrating superiority of TheraSphere personalised dosimetry for HCC patients. They explain how Simplicit90Y enables rapid and effective implementation of TheraSphere personalised dosimetry in clinical practice.
EPOCH: The phase III RCT with Y-90 TheraSphere™, ESMO Symposium
Evaluating 2nd line treatment with Y-90 TheraSphere in patients with colorectal liver metastases. ESMO 2021 Congress, Boston Scientific symposium, September 21st 2021
Evidence and clinical appication of SIRT in early and intermediate HCC
Dr. Irene Bargellini at ECIO 2021 provides evidence on the versatility of SIRT in early HCC disease and on the treatment of heterogeneous intermediate HCC patients with Y90
SIRT: The versatility of current HCC treatment & opportunities for the future
EASL 2021 - Digital Liver Cancer Summit Chair: Prof. Maren Schulze
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.